Immune Deficiency
Conditions
Keywords
Probiotics, Immune function, Natural killer cell activity, Interleukin-12, Interferon-gamma, Immunoglobulin
Brief summary
To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.
Detailed description
A randomized, open-labelled, placebo-controlled study was conducted on 200 nondiabetic, nonobese and elderly (≥60 years) subjects. Over a twelve-week period, the test group consumed one bottle (120 mL) of dairy yogurt each day, whereas the placebo group consumed same volume of low fat milk daily. NK cell activity (%) was measured based on the ratios of effector cells (E; peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562 cells) at E:T= 10:1, 5:1, 2.5:1, 1.25:1 or 0.625:1. In addition, cytokines and immunoglobulin levels measured using commercial kits as manufacturer's instruction.
Interventions
DIETARY_SUPPLEMENTProbiotic yogurt
120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
DIETARY_SUPPLEMENTPlacebo
120 mL of low-fat milk
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Able to give informed consent * Over 60 years old without any health problems * The levels of white blood cells within range 4x10\^3/μL\ 10x10\^3/μL
Exclusion criteria
* Individuals who get a cold * Diabetes * Hypersensitivity or disease history for milk protein * Epilepsy, neurological, or psychological disease * Alcoholism or drug addiction * Liver disease or severe kidney failure disease * Inflammation-related disease * Consumption of other test products or drugs within 1 month prior to screening * Regular consumption of immune-related functional foods including yogurt or milk within 1 month prior to screening * History of inflammation-related disease or taking medication to treat inflammation-related disease within 1 month prior to screening * History of cancer within 5 years * Any inappropriate condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Natural killer cell activity | At baseline |
| Change from baseline natural killer cell activity at 12-week | At baseline and 12-week follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin-12 | At baseline |
| Change from baseline Interleukin-12 at 12-week | At baseline and 12-week follow-up |
| Interferon-gamma | At baseline |
| White blood cell | At baseline |
| Immunoglobulin | At baseline |
| Change from baseline immunoglobulin at 12-week | At baseline and 12-week follow-up |
| Change from baseline Interferon-gamma at 12-week | At baseline and 12-week follow-up |
| Change from baseline white blood cell at 12-week | At baseline and 12-week follow-up |
Countries
South Korea
Outcome results
None listed